**Participant flow diagram**

## Follow-Up

Analysed (n=30)
 Excluded from analysis (give reasons) (n=0)

## Analysis

Analysed (n=30)
 Excluded from analysis (give reasons) (n=0)

Lost to follow-up (give reasons) (n=0)

Discontinued intervention (give reasons) (n= 0)

Lost to follow-up (give reasons) (n=0)

Discontinued intervention (give reasons) (n=0)

## Enrollment

Allocated to intervention (n=30)

 Received allocated intervention (n=30)

 Did not receive allocated intervention (give reasons) (n=0)

## Allocation

Allocated to intervention (n=30)

 Received allocated intervention (n=30)

 Did not receive allocated intervention (give reasons) (n=0)

Randomized (n= 60 )

Excluded (n=90 )

  Not meeting inclusion criteria (n=90 )

  Declined to participate (n= )

  Other reasons (n= )

Assessed for eligibility (n=150)

**Baseline Characteristics**

Table 1: Personal characteristics of studied patients.

|  |  |  |  |
| --- | --- | --- | --- |
|   | Group A (Study) (n=30) | Group B (Control) (N=30) | P value |
| Mean Age (Years) | 7.400±1.6836 | 7.167±1.9134 | 0.618 |
| Male/Female |  11/19 | 13/17 | 0.598 |
| Mean Weight (kg) | 27.550±6.6051 | 27.400±8.0026 | 0.937 |
| Height (cm) | 124.667±9.0528 | 121.233±11.46521 | 0.203 |

Data presented as mean ±standard deviation (SD)

p< 0.05 significant/ comparison was done using chi-square test.

**Outcome measures**

**Table 1:** The clinical score for asthma severity during the observation period after treatment in studied patients

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Group A****Study** **(n= 30)**  |  | Group BControlled (n= 30)  |  | **T** |  | **p-value** |
| **PASS total score 0 min****PASS total score 20 min****PASS total score 40 min****PASS total score 60 min** | **7.433±1.0400****5.667±1.4933****4.200±1.7889****2.567±1.5687** |  | 7.233±.93535.967±1.65014.533± 1.77603.433± 2.1121 |  | **-0.001****0.738****0.724****1.80** |  | **0.996****0.463****0.472****0.0766** |

Data presented as mean ±standard deviation (SD)

**Table 2:** Oxygen saturation assessment during the observation period after treatment in studied patients

**t P value**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **parameters** | **Group A****Study** **(n= 30)**  |  | **Group B****Controlled** **(n= 30)**  |  |
| SaO2 0 min | **90.400±1.5447** |  | 90.200±1.2149 |  |
| SaO220 minSaO2 40 minSaO2 60 min | **94.367±2.4280****95.967±1.3257****97.467±.8604** |  | 93.067±3.372693.833±2.653395.033±2.2512 |  |

-0.557 0.579

1.713 0.092

3.939 0.000

5.530 0.000

Data presented as mean ±standard deviation (SD)

**Table 3:** PEFR assessment during the observation period after treatment in studied patients.

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters** | **Group A****Study** **(n= 30)**  | Group BControlled (n= 30)  | **t P value** |
| PEFR 0 min |  **138.9997±32.3907** | 127.5239±28.1931 | -1.464 0.149 |
|  |  |  |  |
| PEFR20 minPEFR 40 minPEFR 60 min | **165.9890±38.8426****181.5557±39.6994****206.6673±41.3100** | 141.7780±35.57603146.5567±36.57195168.1100±41.31688 | 2.518 0.0153.551 0.0013.615 0.001 |

Data presented as mean ±standard deviation (SD)

**Adverse Events**

There were no adverse events associated with this study.